ABCL logo

ABCL
AbCellera Biologics Inc

8,317
Mkt Cap
$1.16B
Volume
4.31M
52W High
$6.52
52W Low
$1.89
PE Ratio
-6.28
ABCL Fundamentals
Price
$3.62
Prev Close
$3.86
Open
$3.80
50D MA
$3.78
Beta
1.45
Avg. Volume
3.2M
EPS (Annual)
-$0.5533
P/B
1.12
Rev/Employee
$48,377.52
Loading...
Loading...
News
all
press releases
AbCellera Biologics (NASDAQ:ABCL) Trading Down 6.1% - Here's Why
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.1% - Here's What Happened...
MarketBeat·7d ago
News Placeholder
More News
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6% - Here's Why
AbCellera Biologics (NASDAQ:ABCL) Trading Up 11.6% - What's Next...
MarketBeat·8d ago
News Placeholder
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
AbCellera (Nasdaq: ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the...
Business Wire·8d ago
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of AbCellera Biologics from a "hold" rating to a "sell" rating in a research report on Tuesday...
MarketBeat·11d ago
News Placeholder
Citizens Financial Group Inc. RI Acquires Shares of 261,890 AbCellera Biologics Inc. $ABCL
Citizens Financial Group Inc. RI bought a new position in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the third quarter, according to the company in its most recent 13F filing with...
MarketBeat·16d ago
News Placeholder
AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026
AbCellera Biologics (NASDAQ:ABCL) used its presentation at the 2026 JPMorgan Healthcare Conference to outline its shift from a technology-enabled antibody discovery partner toward a company advancing...
MarketBeat·16d ago
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up on Analyst Upgrade
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up on Analyst Upgrade...
MarketBeat·19d ago
News Placeholder
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class...
Business Wire·19d ago
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Trading Up 9.2% - Still a Buy?
AbCellera Biologics (NASDAQ:ABCL) Trading 9.2% Higher - Should You Buy...
MarketBeat·25d ago
News Placeholder
AbCellera Biologics (NASDAQ:ABCL) Cut to Sell at Wall Street Zen
Wall Street Zen lowered AbCellera Biologics from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat·27d ago
<
1
2
...
>

Latest ABCL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.